Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2005

View Archived Issues

A novel EphA2-targeting antibody conjugated to MMAF reverses tumor growth

Takeda offers six-month development update

Enrollment complete in study of ETHOS I stent

Anti-TNF-alpha vaccine works in arthritic mice

Fractalkine identified as a novel target for the treatment of atherosclerosis

Obestatin: a newly identified hormone that suppresses appetite

Neose Technologies receives milestone payment from Novo Nordisk

Acambis begins pivotal program for ChimeriVax-JE

Preliminary results from phase I study of IPL-455903

Sinovac cleared to advance pandemic influenza vaccine into Chinese clinical testing

Wex preparing IND for Tectin

First patient dosed in phase II study of VRX-496 for HIV

FDA approves updated labeling for Lexiva

Research objective met in Arius and Protein Design Labs' collaboration

CF-101 demonstrates efficacy in phase II rheumatoid arthritis trial

Liposome entrapped c-raf antisense oligonucleotide assessed in phase I study

Flurizan taken beyond 1 year improved cognition in Alzheimer's disease patients

D3 antagonists may provide a useful adjunct to levodopa therapy

T-817MA improves beta-amyloid-induced learning deficits in rats

Shire submits BLA for Elaprase for Hunter's syndrome

GlaxoSmithKline seeks Japanese approval for fondaparinux sodium

Theravance prepares and tests 5-HT4 receptor agonists for gastrointestinal disorders

Recent patents disclose novel agents for the treatment of endocrine-related disorders

Belimumab activity, safety revealed in phase II rheumatoid arthritis trial

Animal studies support clinical evaluation of TACI-Ig

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...